核因子κB受体活化因子配体对血管紧张素Ⅱ诱导人肾小球足细胞分泌血管内皮细胞生长因子的影响

Abstract
Figure/Table
References (20)
Related Citation (5)

Download: PDF (0 KB) HTML (41 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of receptor activator of nuclear factor-κB ligand (RANKL)on the secretion of vascular endothelial growth factor(VEGF)induced by angiotensinⅡ (AngⅡ)in human renal podocytes,and to explore whether AngⅡaffecting VEGF expression in podocytes through RANK/RANKL signaling pathway.Methods The human renal podocytes differentiated into dendrites were selected as research subjects.They were dealt with AngⅡin different concentrations (0,1,10,100 nmol/L).Real-time fluorescence quantitative PCR was performed at different time(0,6,12,24 h)to detect the changes in mRNA expression of the genes VEGF,RANK,and RANKL.Then podocytes were stimulated with different doses of RANKL and 100 nmol/LM AngⅡfor 24 h.The expression of VEGF mRNA was detected by RT-PCR and the apoptosis rate of podocytes was detected by flow cytometry.Results AngⅡinduced podocyte expression of VEGF,RANK,and RANKL in a dose-and time-dependent manner(P＜0.05),while excess RANKL showed dose-dependent blockade of VEGF expression increasing (P＜0.05).Compared with the control group,AngⅡsignificantly induced podocyte apoptosis(P＜0.05),while RANKL inhibited podocyte apoptosis induced by AngⅡ (P＜0.05).Conclusion AngⅡmay affect podocyte expression of VEGF through RANK/RANKL signaling pathway.RANKL inhibits the apoptosis of the podocytes induced by AngⅡby regulating the expression of VEGF gene through feedback regulation and protects the kidneys.

Key words： Podocyte AngiotensinⅡ Receptor activator of nuclear factor-&kappa B ligand Vascular endothelial growth factor

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	QI Yue
	ZHU Tao
	QIN Zhi-cheng

Cite this article:

QI Yue,ZHU Tao,QIN Zhi-cheng. Effect of receptor activator of nuclear factor-κB ligand on the secretion of vascular endothelial cell growth factor from human glomerular podocytes induced by angiotensinⅡ[J]. 中国当代医药, 2018, 25(14): 13-16转20.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I14/13

[7]	齐悦.血管紧张素Ⅱ刺激人足细胞表达血管内皮生长因子信号通路的研究[D].太原：山西医科大学，2008.
[8]	邵珊，白波，李荣山，等.全反式维甲酸对高糖培养的人肾小球足细胞synaptopodin蛋白表达的影响[J].中国医药，2012，7（5）：601-602.
[9]	陈瑜，刘超.足细胞损伤与糖尿病肾病[J].中国实用内科杂志，2007，27（23）：1876-1879.
[10]	陈星华，丁国华.肾脏局部血管紧张素Ⅱ与足细胞病变关系的研究进展[J].中国全科医学，2013，16（17）：2053-2056.
[1]	Menon MC，Chuang PY，He CJ.The glomerular filtration barrier： components and crosstalk[J].Int J Nephrol，2012，2012：749010.
[4]	卞帅博，刘佳.氟伐他汀及氯沙坦对血管紧张素Ⅱ诱导人足细胞VEGF表达的影响[J].南京医科大学学报，2011，31（8）：1123-1127.
[2]	QP Li，RZ Shi，JCh Wang，et al.Angiotensin II induces vascular endothelial growth factor synthesis in mesenchymal stem cells[J].Exp Cell Res，2009，312（1）：10-15.
[3]	Kang YS，Park YG，Kim BK，et al.Angiotensin II stimilates the synthesis of vascular endithelial growth factor through the p38 mitogen activated protein kinase pathway in cultured mouse podocytes[J].Mol Endocrinol，2006，36（2）：377-388.
[5]	Lee EY，Shim MS，Kim MJ，et al.Angiotensin Ⅱ receptor blocker attenuates overexpression of vascular endothelial growth factor in diabetic podocytes[J].Exp Mol Med，2004，36（1）：65-70.
[6]	Liu S，Shi W，Xiao H，et al.Receptor activator of NF-kappaB and podocytes：towards a function of a novel receptorligand pair in the survival response of podocyte injury[J].PloS One，2012，7（7）：e41331.
[11]	Zhan Y，Yang L，Wen Y，et al.Yi qi qing re gao attenuates podocyte injury and inhibits vascular endothelial growth factor overexpression in p uromycin aminonucleoside rat model.Evidence-based complementary and alternative medicine[J].Evid-Based Compl Alt，2014，2014（3）：375986.
[12]	Veron D，Reidy K，Marlier A，et al.Induction of podocyte VEGF164 overexpression at different stages of development causes congenital nephrosis or steroid-resistant nephrotic syndrome[J].Am J Pathol，2010，177（5）：2225-2233.
[13]	张丽萍，谭会斌，邢玲玲，等.IgA肾病足细胞损伤中的血管内皮生长因子表达及临床意义[J].中国现代医学杂志，2010，20（14）：2162-2165.
[14]	Sonneveld R，van der Vlag J，Baltissen MP，et al.Glucose specifically regulates TRPC6 expression in the podocyte in an Ang Ⅱ-dependent manner[J].Am J Pathol，2014，184（6）：1715-1726.
[15]	Nijenhuis T，Sloan AJ，Hoenderop JG，et al.Angiotensin Ⅱcontributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway[J].Am J Pathol，2011，179（4）：1719-1732.
[16]	Ren Z，Liang W，Chen C，et al.Angiotensin Ⅱ induces nephrin dephosphorylation and podocyte injury：role of caveolin-1[J].Cell Signal，2012，24（2）：443-450.
[17]	Tanaka S.Signaling axis in osteoclast biology and therapeutic targeting in RANK/RANKL/OPG system[J].Am J Nephrol，2007，27（5）：466-478.
[18]	冯仲林，刘双信，史伟，等.嘌呤霉素氨基核苷肾病肾脏中RANK-RANKL的表达[J].南方医科大学学报，2014，34（1）：65-69.
[19]	Chen XW，Liu WT，Wang YW，et al.Cyclopropanyldehydrocostunolide LJ attenuates high glucose-induced podocyte injury by suppressing RANKL/RANK-mediated NF-κB and MAPK signaling pathways[J].J Diabetes Complications，2016，30（5）：760-769.
[20]	Pupilli C，Lasagni L，Romagnani P，et al.Angiotensin Ⅱstimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells[J].J Am Soc Nephrol，1999，10（2）：245-255.